Literature DB >> 2372583

Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes).

R A Schoenenberger1, W E Haefeli, P Weiss, R F Ritz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2372583      PMCID： PMC1662960          DOI： 10.1136/bmj.300.6736.1375

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion.

Authors:  D Guelon; B Bedock; C Chartier; J P Haberer
Journal:  Am J Cardiol       Date:  1986-09-15       Impact factor: 2.778

2.  Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome.

Authors:  R A Freedman; K P Anderson; L S Green; J W Mason
Journal:  Am J Cardiol       Date:  1987-01-01       Impact factor: 2.778

3.  [Electrophysiological study of pro-arrhythmogenic effects of erythromycin].

Authors:  J Ponsonnaille; B Citron; A Richard; J F Trolese; A Chaperon; B Barret; H Gras
Journal:  Arch Mal Coeur Vaiss       Date:  1988-08

4.  Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin.

Authors:  J M McComb; N P Campbell; J Cleland
Journal:  Am J Cardiol       Date:  1984-10-01       Impact factor: 2.778

5.  Pharmacokinetics of single-dose erythromycin in normal and alcoholic liver disease subjects.

Authors:  P D Kroboth; A Brown; J A Lyon; F J Kroboth; R P Juhl
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191
  5 in total
  10 in total

1.  Torsade de pointes: chaos, sixteen years on?

Authors:  J G Cleland; D M Krikler
Journal:  Br Heart J       Date:  1992-01

2.  Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats.

Authors:  H Ohtani; C Taninaka; E Hanada; H Kotaki; H Sato; Y Sawada; T Iga
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.

Authors:  Scott J C Stanat; Carol G Carlton; William J Crumb; Krishna C Agrawal; Craig W Clarkson
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

Review 4.  Possible risk for cardiac arrhythmia related to intravenous erythromycin.

Authors:  W E Haefeli; R A Schoenenberger; P Weiss; R Ritz
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 5.  Adverse effects of macrolide antibacterials.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 6.  Macrolide antibiotics and the risk of cardiac arrhythmias.

Authors:  Richard K Albert; Joseph L Schuller
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

Review 7.  Advances in the Pharmacogenomics of Adverse Drug Reactions.

Authors:  Susannah L Collins; Daniel F Carr; Munir Pirmohamed
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

8.  Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Michael Gysel; Michelle Methot; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2014-04

Review 9.  Macrolides: From Toxins to Therapeutics.

Authors:  Kiersten D Lenz; Katja E Klosterman; Harshini Mukundan; Jessica Z Kubicek-Sutherland
Journal:  Toxins (Basel)       Date:  2021-05-12       Impact factor: 4.546

Review 10.  The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials.

Authors:  Kim Lewis; Zuhoor Alqahtani; Lauralyn Mcintyre; Saleh Almenawer; Fayez Alshamsi; Andrew Rhodes; Laura Evans; Derek C Angus; Waleed Alhazzani
Journal:  Crit Care       Date:  2016-08-15       Impact factor: 9.097
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.